Results 121 to 130 of about 21,216 (279)

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

open access: yes, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS [PDF]

open access: yes, 2015
Huda Taha,1 Archik Das,2 Satyajit Das1,3 1Integrated Sexual Health Service Coventry and Warwickshire Partnership NHS Trust, Coventry, 2School of Medicine, Birmingham University, Birmingham, 3Coventry University, Coventry, UK Abstract: Dolutegravir (DTG)
Das, A., Das, S., Taha, H.
core   +3 more sources

Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir

open access: yesClinical Pharmacokinetics, 2021
Xiaomei I. Liu   +9 more
semanticscholar   +1 more source

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

open access: yesBrazilian Journal of Infectious Diseases, 2010
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Daria J. Hazuda, PhD
doaj   +1 more source

Highlights from the 24th conference on retroviruses and opportunistic infections, 13-16 February 2017, Seattle, Washington, USA [PDF]

open access: yes, 2017
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
Bhagani, Sanjay   +12 more
core   +5 more sources

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

open access: yesPLoS Medicine, 2018
Background In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART).
C. Kityo   +26 more
semanticscholar   +1 more source

Improvement of neuropsychological performances and reduction of immune-activation markers after probiotic supplementation and change of life-style in an HIV positive male: targeting the microbiota to act on gut-brain axis [PDF]

open access: yes, 2017
The gut-brain axis is widely in uenced by the intestinal microbiota and dysbiosis is consequently associated with a large dysregulation of its functions. Probiotic supplementation, reducing the harmful effects of dysbiosis, has shown positive effects not
Bianchi, Luigi   +8 more
core  

Analysis of Transmitted Resistance to Raltegravir and Selective Pressure among HIV-1-Infected Patients on a Failing HAART in São Paulo, Brazil [PDF]

open access: yes, 2012
We studied the presence of primary resistance to raltegravir (RAL), natural polymorphisms, and selection pressure on HIV-1 integrase. We found a high frequency of integrase polymorphisms related to the resistance to RAL and sequence stability.
Azevedo, R. G.   +5 more
core   +2 more sources

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

open access: yesMalaria Journal, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena   +8 more
doaj   +1 more source

Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults : QDISS Open-Label Trial [PDF]

open access: green, 2021
Nolwenn Hall   +13 more
openalex   +1 more source

Home - About - Disclaimer - Privacy